The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21)
Benzinga · 11h ago
BRIEF-Kempharm Confirms Receipt Of $10 Million Milestone Payment For FDA Approval Of Azstarys™ Per License Agreement With Affiliate Of Gurnet Point Capital · 1d ago
KemPharm confirms receipt of $10M milestone payment linked to Azstarys approval
KemPharm (KMPH) is trading ~7.3% higher in the post-market trading after announcing the receipt of a milestone payment worth $10M from Commave Therapeutics as per the recently revised licensing agreement between the two
Seekingalpha · 1d ago
KemPharm Confirms Receipt of $10 Million Milestone Payment for FDA Approval of AZSTARYS(TM) Per License Agreement with Affiliate of Gurnet Point Capital
Eligible to Receive Additional Near-Term $10 Million Milestone Payment Following DEA Scheduling of SDX
GlobeNewswire · 1d ago
KemPharm Receives $10 Million Milestone Payment for FDA Approval of Azstarys
MT Newswires · 1d ago
DJ KemPharm Price Target Cut to $10.00/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 04/09 11:31
DJ KemPharm Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 04/09 11:31
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8)
Benzinga · 04/09 11:26
KemPharm Amends Licensing Agreement With Gurnet Point Capital, Increases Milestone Payments To $590M
Benzinga · 04/09 11:00
BRIEF-KemPharm Announces Amendment To Licensing Agreement With Gurnet Point Capital Affiliate · 04/08 20:40
KemPharm enters amended licensing agreement for AZSTARYS
KemPharm (KMPH) announces an amendment to the definitive collaboration and license agreement with an affiliate of private investment firm Gurnet Point Capital.Under the terms of the amended License Agreement, KemPharm
Seekingalpha · 04/08 20:35
KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS(TM)
Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and Adds a New Top-Level Tier for Royalties on U.S. Net Sales
GlobeNewswire · 04/08 20:05
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
A slew of drugs, including four new molecular entities, were approved in the month of March. NMEs are drugs that contain active moieties that have never been approved by the Food and Drug Administration previously and are indicators of innovation in drug r...
Benzinga · 04/02 12:01
KemPharm Awarded U.S Patent #10,954,212 'Compositions comprising methylphenidate-prodrugs, processes of making and using the same"*%22&OS=%22*%22&RS=%22*%22
Benzinga · 03/23 11:11
Are Options Traders Betting on a Big Move in KemPharm (KMPH) Stock? · 03/17 19:02
SNDL, ZOM among premarket gainers
Can-Fite BioPharma Ltd. (CANF) +87% on out-licensing psoriasis, liver disease drug rights.SunLink Health Systems, Inc. (SSY) +55% on announcing $2 Million expansion, capital and operating improvements at Trace Regional Hospital.Annovis Bio, Inc.
Seekingalpha · 03/16 12:29
Edgar Online - (EDG = 10Q, 10K) · 03/12 11:07
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/12 05:25
DJ KemPharm, Inc. CEO Travis Mickle on Q4 2020 Results -- Earnings Call Transcript >KMPH
Dow Jones · 03/12 04:34
Webull provides a variety of real-time KMPH stock news. You can receive the latest news about KemPharm through multiple platforms. This information may help you make smarter investment decisions.
About KMPH
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.